XVIVO; The annual CMD provides an updated five-year objective to 2023-2027 - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

XVIVO; The annual CMD provides an updated five-year objective to 2023-2027 - Redeye

{newsItem.title}

XVIVO’s financial target is to reach above an EBIT margin of 20% and above EBITDA margins of 30% supported by among other value drivers, the continuous transformation of the Abdominal margin. There is no specific sales guide but the objectives to double the installed machine base, to transform the EVLP penetration and the secure 15% totals sales share from new markets including Saudi, Brazil and China.

Länk till analysen i sin helhet: https://www.redeye.se/research/856046/xvivo-the-annual-cmd-provides-an-updated-five-year-objective-to-2023-2027?utm_source=finwire&utm_medium=RSS

Nyheter om Xvivo Perfusion

Läses av andra just nu

Om aktien Xvivo Perfusion

Senaste nytt